‌

US Patent 9303259 RNA interference in skin indications

Patent 9303259 was granted and assigned to Rxi Pharmaceuticals Corporation on April, 2016 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors

Is a

Patent attributes

Patent Applicant

Rxi Pharmaceuticals Corporation

Current Assignee

Rxi Pharmaceuticals Corporation

Patent Jurisdiction

United States Patent and Trademark Office

Patent Number

Patent Inventor Names

Dmitry Samarsky0

James Cardia0

Joanne Kamens0

Pamela A. Pavco0

Tod M. Woolf0

William Salomon0

Anastasia Khvorova0

Date of Patent

April 5, 2016

Patent Application Number

14104450

Date Filed

December 12, 2013

Patent Citations Received

US Patent 12077755 Bioactive conjugates for oligonucleotide delivery

0

US Patent 11702659 Optimized anti-FLT1 oligonucleotide compounds for treatment of preeclampsia and other angiogenic disorders

0

US Patent 11753638 Conjugated oligonucleotides

US Patent 11767527 Modified oligonucleotides targeting SNPs

US Patent 11926828 Methods for treating aging and skin disorders using nucleic acids targeting TYR or MMP1

0

US Patent 12024706 Modified oligonucleotides targeting SNPs

0

0

Patent Primary Examiner

Patent abstract

The present invention relates to RNAi constructs with improved tissue and cellular uptake characteristics and methods of use of these compounds in dermal applications.

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 9303259 RNA interference in skin indications

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Golden Query Tool

By using this site, you agree to our Terms of Service.